In an era characterized by translation of novel scientific concepts towards an array of competing clinical candidates, treatment algorithms across the spectrum of cancer types are on the verge of confronting a proverbial “nice problem to have”, with multiple modalities and products therein from which to choose. Old meets new against a backdrop of unabating unmet need and burgeoning financial strain. Which modalities can be combined, sequenced, or replaced? Will any reign supreme? At what point does cost and convenience outweigh efficacy and tolerability? Will there ever be enough evidence to support clinical decision-making among different modalities? If any of these questions have piqued your interested, please join the organizers of Cancer Progress for one final session during which we will engage in a collegial discussion – interspersed at times with respectful debate, juvenile bickering, and perhaps some poetry slam – on the all-important topic of modalities in the modern age of cancer treatment.
- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting
- James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting
- Serom Lee, PhD, Senior Consultant, Cello Health BioConsulting
- Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting
- Joel S. Sandler, PhD, Principal, Cancer Cell Therapy Lead, Cello Health BioConsulting